Getting old isn't all it's cracked up to be.
When I was young, dumb, and all too daring, I took chances that in hindsight were pretty boneheaded, and I'm still paying for them.
Once I even jumped off the roof of my grandmother's house, thinking I was going to catch the storm drain as I dropped by. Why I believed that I'm not sure.
Instead, I ended up in the hospital needing five reconstructive surgeries that included bone grafts donated from my own hip.
In fact, today I still suffer from a dull ache in the same hip, which is a decent trade off because I can still use my arm.
Fortunately, medicine has come a long way since the day I stood on that roof eyeing up that gutter.
Today someone in the same situation would turn to a biotech company to provide the material needed for that surgery, not a human donor.
This is one of the reasons I like Bacterin International Holdings Inc. (AMEX: BONE)
Breaking Down Bacterin
Bacterin designs, manufactures and markets revolutionary dermal and skeletal health products, bone graft material, biological scaffolds and related medical devices.
They also design and produce bioactive, anti-microbial coatings for implantable devices that act as barriers to infection.
Their total potential markets in the United States alone are estimated at over $8.5 billion. Of that, Bacterin has gained a small but growing percentage.
But here's what more impressive: